MT1002 for Injection

DRUG3 trials

Sponsors

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Conditions

ACS - Acute Coronary SyndromeAcute Coronary SyndromeHealthy

Phase 1

Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

CompletedNCT04116840

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Healthy

Start: 2019-04-29End: 2019-11-27Updated: 2022-07-29

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

TerminatedNCT05323136

Shaanxi Micot Pharmaceutical Technology Co., Ltd.ACS - Acute Coronary Syndrome

Start: 2022-04-15End: 2022-06-29Updated: 2023-01-26

Phase 2

MT1002 Phase II Study in ACS Patients With PCI

TerminatedNCT04723186

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Acute Coronary Syndrome

Start: 2020-12-02End: 2023-08-31Updated: 2026-05-27